BioSpace News Archive

Verona Pharma plc, a clinical-stage biopharmaceutical company focused on respiratory diseases, announces its financial results for the three months ended September 30, 2022, and provides a corporate update.

TILT Biotherapeutics, a clinical-stage biotechnology company developing cancer immunotherapies, announces that the company has opened an office in Boston, to support its increasing US clinical development, partnering and fund-raising activities.

Exyte GmbH, a global leader in the design, engineering, and delivery of high-tech facilities, continues its strong performance during the first nine months of fiscal year 2022 successfully progressing on its accelerated growth path, its ‘Pathway to Ten’.

RadNet, Inc. (NASDAQ: RDNT), a national leader in providing high-quality, cost-effective, fixed-site outpatient diagnostic imaging services through a network of 349 owned and operated outpatient imaging centers, today reported financial results for its third quarter of 2022.

ProQR Therapeutics N.V., a company dedicated to changing lives through the creation of transformative RNA therapies, reported its financial and operating results for the third quarter ended September 30, 2022, and provided a business update.

ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (ANI or the Company) today announced business highlights and financial results for the three and nine months ended September 30, 2022.

IsoPlexis Corporation, a company empowering labs to leverage the cells and proteome changing the course of human health, announced it will be participating in the following investor conferences.

Conformis, Inc. announced that it will effect a 1-for-25 reverse stock split at 5:00 p.m. Eastern time.

TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today reported financial results and provided a business update for the third quarter ended September 30, 2022.

Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced positive clinical data for TRV045, its selective sphingosine-1-phosphate subtype 1 (S1P1) receptor modulator.